FDA clarifies criteria for 'sameness' of gene therapies

In new draft guidance, FDA clarified its criteria for determining whether a gene therapy is the same as an existing treatment when considering its eligibility for Orphan Drug designation and exclusivity.

The agency said that while prior orphan drug regulations have

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE